The Ascenta Therapeutics spinout has completed a series B round that will go to developing its pipeline of small-molecule treatments for cancer, hepatitis B and age-related diseases.
Ascentage Pharma, a China-based oncology therapeutics development spinout of biopharmaceutical company Ascenta Therapeutics, closed its series B round at RMB500m ($72m) yesterday.
The round was led by Future Industry Investment Fund, a private equity branch of the Chinese state-owned State Development & Investment Corporation, and included Shiyu Capital, Hidragon Capital, Founder Kip Capital, YuanMing Capital, Oriza Venture Fund and Efung Capital.
Ascentage is developing small-molecule drugs to treat cancer, hepatitis B and age-related diseases, and has six candidates in phase…
